Periodontal diseases are chronic inflammation caused by particular types of bacteria and have been recognized as a cause of tooth loss in adults. These bacteria which invade periodontal tissue are phagocytosed mainly by monocytes and macrophages in this immune response, and will be presented to lymphocytes. Recently, therapies for regenerating periodontal tissues have been used extensively to treat periodontal disease, and in particular, enamel matrix derivative (EMD) is commonly used for such therapies in Japan. Amelogenin is a type of the extracellular matrix protein that accounts for 90% of the constituents of EMD. In this study, we carried out a detailed microarray analysis in order to evaluate a gene group involved in amelogenin stimuli in the human monocytic cell line U-937. Microarray analysis revealed that statistically significant changes were apparent in 273 genes (163 up-regulated and 110 down-regulated) subsequent to 4 h of amelogenin stimulation. The most highly enriched categories included "cell cycle", "DNA replication", and "DNA repair" in up-regulated annotation terms. On the other hand, "type I diabetes mellitus", "allograft rejection", and "graft versus host disease" were observed in down-regulated annotation terms. Specifically, the gene expression of major to compatibility complex (MHC) class I/II and CD80/86 was impaired in U937 cells after stimulation with amelogenin. In addition, the results of heat-map showed that the gene expression of inflammatory cytokine such as tumor necrosis factor (TFN), interleukin-18 (IL-18), and CXCL16 was markedly decreased after stimulation of monocytes with amelogenin. In conclusion, the findings of our study showed that by inducing monocyte growth through the suppression of the antigen-presenting ability of U937 cells, amelogenin may affect the immune responses of periodontal tissues originating from monocytes. Examining the effects of amelogenin on the transformation of macrophages differentiating from monocytes may establish a molecular baHow to cite this paper:
Introduction
Periodontal diseases are chronic inflammation caused by particular types of periodontal disease-causing bacteria. Because they cause resorption of the alveolar bone, they have been recognized as a cause of tooth loss in adults aged 40 years or older [1] . Teeth are supported by surrounding tissues known as periodontal tissues and are composed of four types of tissues: gingival soft tissue; periodontal ligament around the dental root; cementum, comprising the hard tissue at the surface of the dental root; and alveolar bone [2] . Treatment of periodontal disease has mainly consisted of removing the causative lesion, such as tooth-brushing instruction aimed at improving the condition of the oral cavity through cleaning, or removal of subgingival calculi by periodontal scaling and root planing or flap surgery. The main purpose of these treatments is to suppress the progression of periodontal disease [3] . However, recently developed regenerative therapies aimed at regenerating periodontal tissues have been used extensively to treat periodontal disease, and some success has been achieved [4] . In Japan, enamel matrix derivative (EMD) extracted from the tooth germs of young pigs is commonly used for such therapies. EMD has been commercialized under the name Emdogain® gel [5] . Among periodontal tissue regeneration materials that contain bioactive proteins such as growth factors, Emdogain® gel is currently the only treatment approved by the Japanese Ministry of Health, Labour and Welfare. However, although numerous studies have attempted to determine the mechanism of action of EMD, the molecular aspects of periodontal tissue regeneration at the signal transduction level remain unclear. Additionally, periodontal surgical treatment using EMD has been empirically shown to promote healing and is associated with reduced pain and swelling [6] . Previous reports have shown that amelogenin had an anti-inflammatory effect from the perspective of pro-inflammatory and anti-inflammatory cytokine production [7] .
Amelogenin is a type of the extracellular matrix protein that accounts for 90% of the constituents of EMD and is a primary molecule in periodontal tissue regeneration using EMD [8] . In the field of medicine, extracellular matrix has been applied to wound healing and regenerative therapy, and amelogenin has been used to treat refractory pressure ulcers under the trade name Xelma® [9] . The practical application of amelogenin in periodontal tissue regeneration was developed based on the biological imitation of the dental development environment [10] . Amelogenin is secreted by ameloblasts during the formation of tooth germs and is thought to be involved in periodontal tissue formation, beginning with cementum which is deposited in the dentin [11] . Amelogenin-knockout mice exhibited cementum hypoplasia and abnormal differentiation of osteoclasts in their oral cavity [12] . Recombinant amelogenin has been reported to cause periodontal tissue regeneration in laboratory animals [13] . In periodontal ligament cells and osteoblasts, which are important for periodontal tissue regeneration, amelogenin-associated molecules should be identified in order to establish the molecular basis of their effects. By proteomic analysis focusing on amelogenin, which is a major protein in EMD, we identified a new group of amelogenin-associated molecules such as Grp78 in osteoblasts [14] . In addition, the association between amelogenin (rM180) and Grp78 has been reported to be involved in the cellular migratory capacity of periodontal ligament stem cells [15] .
When periodontal disease-causing bacteria invade periodontal tissues, oral bacteria are phagocytosed by neutrophils in a non-specific manner in order to confer protection to the host. However, if this is the only protection and if it is insufficient, the organism will develop a full immune response. In this immune response, antigens are phagocytosed mainly by monocytes and macrophages and will be presented to lymphocytes (antigen-presenting reaction). This explains why monocytes are considered the basis of the immune responses. In our study, we examined the effects of amelogenin on immune responses. We carried out a detailed microarray analysis in order to evaluate a gene group involved in amelogenin stimuli in the human monocytic cell line U-937.
Materials and Methods

Cell Culture
U937 human monocytic cell line was purchased from RIKEN BioResouce Center (Ibaraki, Japan). U937 cells were cultured in RPMI-1640medium containing 10% heat-inactivated fetal bovine serum (FBS), penicillin, and streptomycin at 37˚C in a 5% CO 2 incubator. Cells were sub-cultured every 48 -72 h, inoculum being 5 × 10 5 /ml and cell viability (>95%) was confirmed by trypan blue exclusion.
Recombinant Protein
Cloning and expression of a glutathione S-transferase (GST) full-length recombinant amelogeninfusion (GST-rM180), and the purification of rM180 were previously described [14] . Removal of endotoxin from rM180 was confirmed by Limulus Amebocyte Lysate Assay (Endotoxin Level: 10 μg of rM180 < 0.03 EU). U937 cells were stimulated with rM180 (10 μg/mL) for 4 h, 8 h, 12 h, and 24 h.
Gene Expression Profiling by Microarray
Total RNA was isolated with Isogen 2 (Nippon Gene, Tokyo, Japan) and purified BeadChip (Illumina, San Diego, CA, USA). The chip was hybridized at 58˚C for 18 h, washed, stained with fluorescent reagents, and scanned using a BeadArray Reader (Illumina). Relative hybridization intensities and background hybridization values were calculated using Genome Studio v1.8 (Illumina). Using procedures recommended by Illumina, the raw signal intensities of five samples were normalized using quantile algorithms from the "lumi" [16] and "preprocess Core" library packages [17] on the Bioconductor software [18] . Probes flagged as "Detection P-value < 0.05" in at least one sample were selected for analysis. To identify genes that were up regulated or down regulated, we calculated the intensity-based Z-scores [19] and the ratios (non-log scaled fold-change) of the normalized signal intensities for each probe, comparing the control and experiment samples. Next, we established criteria for differentially expressed genes (DIGs): upregulated genes, Z-score ≥ 2.0 and ratio ≥ 1.5-fold; down regulated genes, Z-score ≤ −2.0 and ratio ≤0.66.
Microarray Analysis
To determine the cellular effects of these DIGs and significant pathway enrichment, we used the Database for Annotation, Visualization and Integrated Discovery (DAVID) software (http://david.abcc.ncifcrf.gov/home.jsp) [20] . To characterize the biological processes affected by DIGs, we used Gene Ontology (GO) and the functional annotation-clustering feature of DAVID. The functional annotation clustering tool measures the similarities between GO terms based on the extent of their associated genes, and assembles similar and redundant GO terms into annotation clusters. Each clustered GO term is assigned a Fisher Exact P-value representing the degree of enrichment of the GO term within the DIGs. Each cluster is assigned an enrichment score signifying its biological significance. A biologically significant cluster (high enrichment score) is generated only when the majority of the GO term members have significant enrichment values. Functional annotation clusters with an enrichment-score of >1.3 were considered significant [21] , and the resulting clusters were further filtered to retain only those GO terms with P values of <0.05. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was also performed to analyze the significance of biological functions identified in large-scale transcriptome data. In addition, we generated a heat-map using Multi Experiment Viewer (MeV) software (http://www.tm4.org/mev.html) [22] and a hierarchical clustering (HCL) method for gene sorting. The inflammation-associated genes were identified as GO terms containing "inflammatory response". Color indicates the distance from the median of each column. "Pearson correlation" and "average linkage clustering" were used to determine distance and linkage, respectively. Microarray data analysis was supported by Cell Innovator (http://www.cell-innovator.com/).
Results
Amelogenin Up-Regulates the Expression Profiles of Cell Proliferation-Associated Genes in U937 Cells
To characterize the biological effects of amelogenin in monocytes, we performed transcriptional profiling of U937 cells using microarray analysis. Samples of U937 cells were stimulated with rM180 for 4 h, 8h, 12h, or 24 h. U937 cells in the absence of rM180 stimulation were used as the control sample (unstimulated). (Table 1 and Figure 2 ). The most highly enriched categories included "cell cycle", "DNA replication", "DNA repair", and "ribosome". These results indicate that amelogenin induces the expression levels of genes encoding cell proliferation in U937 cells.
Amelogenin down-Regulates the Expression Profiles of Antigen Presentation-Associated Genes in U937 Cells
On the other hand, we also performed functional annotation clustering of the DIGs following 4, 8, 12 h, and 24 h of rM180 treatment to identify significant down-regulated annotation terms (Table 2 and Figure 3 ). The most highly enriched categories included "type I diabetes mellitus", "allograft rejection", and "graft versus host disease". Specifically, the gene expression of major his to compatibility complex (MHC)class I/II and CD80/86 were impaired in U937 cells after stimulation with rM180 ( Figure 3 ).
Our results showed that amelogenin inhibits the expression levels of genes encoding antigen presentation in U937 cells.
Amelogenin Down-Regulates the Expression Profiles of Inflammation-Associated Genes in U937 Cells
Since amelogenin plays an inhibitory role in the antigen presentation of U937 DAVID v6.7 functional annotation bioinformatics microarray analysis software was used to obtain the functional annotation clustering. Only GO pathway terms that showed statistically significantly differences in the amount of genes (compared unstimulated vs. rM180 4h, 8h, 12h, and 24h) are shown (P-value ≤ 0.05).
Discussion
When considering the onset of periodontal diseases, it may appear that oral bacteria act as antigens and initiate an inflammation reaction; however, the constituents of oral bacteria, namely their outer membrane proteins, pili, and lipopolysaccharides, have a diverse range of antigenicity [23] . In addition, they activate have a strong activating effect on monocytes [24] and are important for determining the etiopathology of periodontal diseases involving inflammation and infection due to gram-negative bacteria. The amelogenin used in this study was a recombinant protein from Escherichia coli, but because Triton X was used in the purification process, the level of endotoxin was confirmed to be 0.03 EU/L or lower when 10 mg amelogenin was used; therefore, the stimulatory effect of amelogenin on monocytes with lipopolysaccharides from E. coli was negligible.
In scatter plot analysis aimed at confirming the temporal changes in gene expression caused by amelogenin stimuli, our findings showed that unlike cytokines, amelogenin did not induce notable variations in gene expression; our findings also confirmed that the effects of amelogenin generally developed at a relatively early stage (4h) (Figure 1 ). We previously reported that the growth of osteoblasts and the migration of periodontal ligament stem cells were enhanced by amelogenin [14] [15] . In other studies, amelogenin was reported to enhance the differentiation of cementoblasts as well as that of periodontal ligament cells;
however, the results of the present study suggest that amelogenin promotes cell growth mainly by enhancing the gene expression of proliferating cell nuclear antigen, CycE, and Cdc45 in monocytes (Figure 2 ). Amelogenin has been reported to exert various effects depending on the cell type and stage of differentiation; in addition, Emdogain Gel has been reported to enhance the growth and differentiation of osteoblasts, cementoblasts, and periodontal ligament cells, and to inhibit the in growth of gingival epithelial cells toward bony defects [25] . The U-937 cells used in this study were monocytic cells; the effects after differentiation of these cells into macrophages should be examined in future studies. Previous clinical reports have shown that while the periodontal tissue regeneration effect of Emdogain persisted over a few years, the microarray analyses results revealed that the stimulatory effect of amelogenin on monocytes was limited to the early stages. This is thought to be because monocytes were floating cells and that amelogenin was not affected as a scaffold for the extracellular matrix. The pathways inhibited by amelogenin may include antigen presentation pathways such as MHC class I/II and CD80/86 ( Figure 3) . Generally, the process of cell growth and differentiation includes a number of conflicting issues, and our findings showed that because of the proliferative effect of amelogenin on monocytes, amelogenin may have inhibited the latter's differentiation into macrophages responsible for antigen presentation. In addition, candidate pathways for the stimulation of monocytes by amelogenin include intracellular uptake through phagocytosis and endocytosis and receptor-mediated signal transduction. However, because of the impaired antigen-presenting ability, the phagocytic pathway is highly likely to be excluded. We previously reported that GRP78
on the cell membrane of periodontal ligament stem cells served as a receptor for amelogenin [15] . GRP78 is a ubiquitous chaperone protein present mainly in the endoplasmic reticulum [26] , but in undifferentiated stem cells, it is also expressed on the cell membrane [27] and has been reported to function as a receptor for Cript [28] and DMP1 [29] . GRP78 is also thought to be expressed in the U-937 cell line composed of monocytes, but no previous studies have eva- further analysis because monocytic cell lines before differentiation were used in this study. In addition, gingival fibroblasts are host cells involved in the construction of periodontal connective tissues, but around monocytes, they control the environment of periodontal tissues. Therefore, while the extracellular matrix is produced in healthy periodontal tissues, the matrix produces substrate-degrading enzymes such as collagenases while regulating its own synthesis and degradation, thereby constantly restructuring the gingival tissues [34] . However, when an inflammatory substance spreads in the connective tissues and causes periodontal disease, gingival fibroblasts become the target cells of various cytokines produced by immunocompetent cells such as monocytes [35] [36] . In addition, gingival fibroblasts produce various cytokines and play a role in some cytokine networks [37] . Thus, at the site of the inflammation in the connective tissue, gingival fibroblasts control and regulate the periodontal tissue environment to efficiently establish immune responses.
In conclusion, the findings of our study showed that by inducing monocyte growth through the suppression of the antigen-presenting ability of these cells, amelogenin may affect the immune responses of periodontal tissues originating from monocytes. Examining the effects of amelogenin on the transformation of macrophages differentiating from monocytes, as well as on gingival fibroblasts, may establish a molecular basis for the anti-inflammatory effect of amelogenin in periodontal tissues.
